The approval was based on the results of the phase 3 ENDEAVOR study.
A variation to the marketing authorization of carfilzomib (Kyprolis)—it’s use in combination with dexamethasone—was approved today by the European Commission (EC) for adult patients with multiple myeloma who have advanced on at least 1 prior therapy.
The approval was based on phase 3 data submitted by Amgen, the developer of carfilzomib, from the ENDEAVOR trial. The head-to-head trial compared carfilzomib plus dexamethasone (Kd) against bortezomib plus dexamethasone (Vd) and found that Kd achieved 18.7 months of progression-free survival, compared with 9.4 months in those receiving Vd (HR = 0.53; 95% CI, 0.44-0.65; P<.0001), according to a press release. Kd, the press release said, also showed improvement over Vd for secondary endpoints such as the rate of complete response (12.5% for Kd vs 6.2% for Vd, P<.0001).
“In the Phase 3 head-to-head trial, Kyprolis in combination with dexamethasone doubled the time patients lived without their cancer progressing, as well as the rates of complete response compared to bortezomib and dexamethasone,” said Sean E. Harper, MD, executive vice president of Research and Development at Amgen, in a statement. “Kyprolis-based regimens have now shown superiority over two former standard-of-care treatment options for relapsed multiple myeloma patients, reinforcing Kyproli’' place as a foundational therapy in this patient population.
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More